[AsCNP_P23] ポスター23
Schizophrenia 2

2019年10月12日(土) 16:40 〜 18:10 ポスター会場 (多目的ホール)

Chair: ‌Chieh-Hsin LIN (Kaohsiung Chang Gung Memorial Hospital, Taiwan)

+全てマイスケジュールに登録

16:40 〜 16:45

[AsCNP-P23-1] Early improvement of PANSS items in patients with schizophrenia treated with brexpiprazole: a post hoc analysis of three randomized studies

^○Catherine WEISS¹, Stine Rasmussen MEEHAN², John OUYANG³, Mary HOBART¹ (1. Department of Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., 2. Department of Medical Affairs Psychiatry, H. Lundbeck A/S, 3. Department of Biostatistics, Otsuka Pharmaceutical Development & Commercialization Inc.)

16:45 〜 16:50

[AsCNP-P23-2] Symptomatic and functional response to brexpiprazole treatment in patients with acute schizophrenia by age

^○Catherine WEISS¹, Erin MACKENZIE², Francois THERRIEN³, Peter ZHANG⁴, Stine Rasmussen MEEHAN⁵ (1. Department of Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., 2. Department of Medical Affairs, Lundbeck Canada Inc., 3. Department of Medical Affairs, Otsuka Canada Pharmaceutical Inc., 4. Department of Biostatistics, Otsuka Pharmaceutical Development & Commercialization Inc, 5. Department of Medical Affairs Psychiatry, H. Lundbeck A/S)

16:50 〜 16:55

[AsCNP-P23-3] Efficacy and Safety of Lurasidone in Acutely Psychotic Patients with Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (JEWEL Study)

^○Kentaro TAKAI¹, Masaomi IYO², Jun ISHIGOOKA³, Masatoshi NAKAMURA¹, Reiko SAKAGUCHI¹, Keisuke OKAMOTO¹, Teruhiko HIGUCHI^{4, 5} (1. Sumitomo Dainippon Pharma Co., Ltd., Japan, 2. Chiba University Graduate School of Medicine, Japan, 3. Institute of CNS Pharmacology, Japan, 4. Japan Depression Center, Japan, 5. The National Center of Neurology and Psychiatry, Japan)

16:55 〜 17:00

[AsCNP-P23-4] The Attitude of Schizophrenic Patients Towards Antipsychotic Long-Acting Injections

^○Nan-Ying CHIU^{1, 2}, Cheng-Ju CHANG¹, Jeng-Fang LIN¹, Lin-Chi CHIU¹, Wen-Yu HSU², Ting-Gang CHANG², Tzu-Yun YANG² (1. Department of Psychiatry, Evergreen Campus, Lugang Christian Hospital, 2. Department of Psychiatry, Changhua Christian Hospital, Changhua, Taiwan)

17:00 〜 17:05

[AsCNP-P23-5] Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: A pilot open-labeled study

^○Masahiro TAKESHIMA, Kazuo MISHIMA (Department of Neuropsychiatry, Akita University Graduate School of Medicine)

講演取消

17:05 〜 17:10

[AsCNP-P23-6] Efficacy and side effect of Pyridoxamine for patients with schizophrenia

^○Mitsuhiro MIYASHITA, Kazuya TORIUMI, Kazuhiro SUZUKI, Yasue HORIUCHI, Akane YOSHIKAWA, Akiko KOBORI, Masanari ITOKAWA, Makoto ARAI (Project for Schizophrenia Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan)

17:10 〜 17:15

[AsCNP-P23-7] Are "ALL" of neurological symptoms with schizophrenia induced by antipsychotics? –Possibility of Niemann–Pick disease type C–

^○Kumiko FUJII¹, Masamitsu MAEKAWA², Yuji OZEKI³, Yoshikatsu ETO⁴, Takahiro SAITO⁵, Masataka SHINOZAKI¹, Yosefu ARIME⁶, Takahide NAGASHIMA^{7, 8}, Hiroaki OKAYASU¹, Kazutaka SHIMODA¹ (1. Department of Psychiatry, Dokkyo Medical University School of Medicine, 2. Pharmaceutical Sciences, Tohoku University Hospital, 3. Department of Psychiatry, Shiga University of Medical Science, 4. Advanced Clinical Research Center, Institute for Neurological Disorders, 5. Yokohama Camellia Hospital, 6. Center for Research Support, Dokkyo Medical University School of Medicine, 7. Department of Neurology, Japanese Red Cross Ashikaga Hospital, 8. Department of Neurology, Dokkyo Medical University School of Medicine)